Securing a
healthier future
At GPN Vaccines, we are committed to advancing public health by developing innovative vaccines against preventable infectious diseases, ensuring a healthier future for all.
MISSION
Innovative global health solutions
GPN Vaccines is a clinical-stage company focused on creating innovative vaccines that offer robust protection against the world’s most important bacterial pathogens.
Innovative Vaccines
Scientific Excellence
Global Collaboration
Technology
A new era in
vaccine development
Our vaccines are based on proprietary strains of bacteria that have been modified to be safe and highly effective.
Clinical Trials
Participate in ground breaking research
Join us in pioneering the next generation of vaccines to prevent pneumococcal disease and in so doing contribute to advancing global health. Whether you have experience with clinical trials or are considering participating for the first time, explore our clinical trials page for more information and check your eligibility to see how you can get involved in advancing vaccine research.
Am I Eligible?
Learn more about the requirements to participate in our clinical trials and contribute to advancing the development of our innovative vaccines.
Events
Upcoming conferences
News
Latest updates
14/07/2025GPN Vaccines reports strong immunogenicity data in older adults independent of previous pneumococcal vaccination status with good tolerability and sustained immunogenicity
Read articleAdelaide, Australia, 14th July 2025 GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to…
- 12/06/2025
Notice to Scheme Shareholders
Read articleOn 12 June 2025, GPN AUS and GPN USA signed a Deed of Variation to the Scheme Implementation…
27/05/2025GPN Vaccines Shareholders Vote in Favour of Re-domiciliation of the Company to the United States of America; Notice of Hearing to Approve Scheme of Arrangement
Read articleCanberra, Australia, 27th May 2025 GPN Vaccines Ltd is pleased to announce the Company’s shareholders have voted unanimously…
PARTNERSHIPS
